A novel way to isolate MSCs from umbilical cords.
Liu Liu,Xiaoyin Zhao,Pengfei Li,Guangfeng Zhao,Yaping Wang,Yali Hu,Yayi Hou
DOI: https://doi.org/10.1002/eji.201142356
2012-01-01
European Journal of Immunology
Abstract:Mesenchymal stem cells (MSCs) not only possess extensive self-renewal potential and can modulate immune cell activation 1, but also they are easily expanded and stored ex vivo, and are considered to be “immune privileged.” MSCs modulate the function of immune cells, including T and B lymphocytes, dendritic cells, and natural killer cells, inhibit their proliferation and alter their cytokine secretion. Previous data from our group and others 2-4 demonstrated the immunosuppressive and antiinflammatory effects of MSCs in the treatment of several animal disease models including autoimmune diseases. As a result of these unique qualities, MSCs are attractive candidates in stem cell-based therapy. The first successful isolation of fibroblast-like colonies from bone marrow, that is, MSCs, was described four decades ago by Friedenstein et al. 5. The isolation method was based on the adherence of bone marrow-derived, fibroblast-like cells to the plastic cell culture plate, and a concomitant lack of adherence of bone marrow-derived hematopoietic cells. MSCs separated by adherence have uniform cell morphology and long-term culture expansion, and the cost of this method is low that makes it desirable as a practical method of production. However, it is reported that MSC separation using the traditional cell-adherent method will not yield good results because MSCs are rare in tissue; the proportion of MSCs in the bone marrow is less than 1:10,000 mononuclear cells 6, 7. Therefore, it is difficult to obtain enough MSCs from bone marrow for medical use. In addition, the maternal–fetal interface is an important source of MSCs, and several groups have isolated MSCs from umbilical cord, placenta, and decidua 8-10. Umbilical cord tissue, which is considered as a clinical waste, is the most stable and readily available source of MSCs and of worth studying. Florian et al. 11 reported that cell isolation protocols have a major impact on the functional activity of bone marrow-derived progenitor cells, highlighting the importance of optimizing MSC isolation protocols. There are four methods reported to separate MSCs: (i) flow cyto-metrical sorting 12; (ii) magnetic separation 13; (iii) density gradient centrifugation 14; and (iv) the cell plastic adherence method 15, 16. Since there are no specific surface markers for MSCs, it is difficult to separate MSCs from the digested cell pellet 17. Although several reports describe the use of CD133, CD271, and CD105 as markers to separate MSCs 18-20, this method also requires several negative markers (CD3, CD14, CD19, CD38, and CD66b) to assist sorting. In addition, flow cytometrical sorting and magnetic separation have large effects on cell viability and require sophisticated equipment. Therefore, these methods are not yet widely used. Density gradient centrifugation, on the other hand, also requires sophisticated equipment and a suitable separation medium and is therefore not suitable for large-scale production of MSCs. It should be noted that all the methods described to isolate MSCs require digestion of the tissue to obtain a single-cell suspension. Since umbilical cords are hard to digest by the traditional digestive enzyme collagen, and long-term digestion will affect the cell viability, there is a dilemma between obtaining a single-cell suspension and obtaining high cell viability. A few groups also use a tissue explants adherent method to separate MSCs 21 that seems to avoid this problem. However, the traditional tissue explants adherent method has also some serious drawbacks such as the low adherence of the tissue to the plastic cell culture plate, and the long time for separation 21. Therefore, we combined the methods of isolating MSCs from plastic-adherent tissue and digested single-cell suspension, using a novel, semi-tissue-adherent method to quickly obtain large amount of MSCs from umbilical cord (UC-MSCs). Compared with the traditional method, the number of steps in this novel method is less and the total separation time is short (Fig. 1A). Using our technique, a mild digestion of umbilical cords released some MSCs from the tissue, and also allowed some incompletely digested tissue to adhere to plastic; MSCs inside the tissue could then migrate to the plastic and expand (Fig. 1B). We also improved the formula of digestive enzymes, add hyaluronidase and dispase that prevented unwanted clumping of cells cultured in suspension. Adherent cells with fibroblastic morphology could be observed as early as 24 h in culture. The cells formed a monolayer of homogeneous bipolar spindle-like cells with a whirlpool-like array within 1 week of culture (Fig. 1B). UC-MSCs were then serially passaged to examine their expansion potential and determined to expand readily for up to 2 weeks (Fig. 1D). We compared the speed of mesenchymal cell isolation using our novel method with that of the traditional methods and found that the novel method yields MSCs much faster than the other two methods (Fig. 1C). Furthermore, after three cell passages, the adherent cells were symmetric with phenotypic surface antigens. The UC-MSCs shared most of their phenotype with bone marrow-derived MSCs (BM-MSCs) as reported, including positivity for CD29, CD44, CD90, CD105 (SH2), CD73 (SH3), and HLA-ABC, negativity for CD19, CD11b, CD14, CD34, and CD31 (endothelial cell marker), and HLA-DR (Fig. 2A). BM-MSCs secrete several soluble factors to exercise their immunosuppressive properties, such as IL-6, TGF-β, IDO, VEGF (vascular endothelial growth factor), and COX-2 22. To determine whether UC-MSCs isolated by our novel method also express those factors, we measured mRNA expression of these factors. UC-MSCs expressed significant amounts of VEGF, IL-6, TGF-β, and COX-2 (Fig. 2B). We also demonstrated that after 72 h coculture with purified human T cells, the UC-MSCs inhibited T-cell proliferation in response to mitogen treatment (Fig. 2C). In conclusion, we have developed a novel method of isolating MSCs from umbilical cords for stem cell therapy, which is much easier and faster than traditional methods. The MSCs isolated using our method exhibited the expansion potential, immune phenotype, and immunosuppressive properties of BM-MSCs. This work was supported by the grants from the National Natural Science Foundation (project number: 81072410), the Special Research Grant of Jiangsu Province Department of Health (project number: XK200709 and JHB2011–1), and a special grant for maternal-fetal medicine from Jiangsu province health department of China (project number: 81070508). The authors declare no financial or commercial conflict of interest. Disclaimer: Supplementary materials have been peer-reviewed but not copyedited. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.